SurvivalMeth: a web server to investigate the effect of DNA methylation-related functional elements on prognosis

Aberrant DNA methylation is a fundamental characterization of epigenetics for carcinogenesis. Abnormality of DNA methylation-related functional elements (DMFEs) may lead to dysfunction of regulatory genes in the progression of cancers, contributing to prognosis of many cancers. There is an urgent need to construct a tool to comprehensively assess the impact of DMFEs on prognosis. Therefore, we developed SurvivalMeth (http://bio-bigdata.hrbmu.edu.cn/survivalmeth) to explore the prognosis-related DMFEs, which documented many kinds of DMFEs, including 309,465 CpG island-related elements, 104,748 transcript-related elements, 77,634 repeat elements, as well as cell-type specific 1,689,653 super enhancers (SE) and 1,304,902 CTCF binding regions for analysis. SurvivalMeth is a convenient tool which collected DNA methylation profiles of 36 cancers and allowed users to query their genes of interest in different datasets for prognosis. Furthermore, SurvivalMeth not only integrated different combinations, including single DMFE, multiple DMFEs, SEs and clinical data, to perform survival analysis on preupload data but also allowed for uploading customized DNA methylation profile of DMFEs from various diseases to analyze. SurvivalMeth provided a comprehensive resource and automated analysis for prognostic DMFEs, including DMFE methylation level, correlation analysis, clinical analysis, differential analysis, DMFE annotation, survival-related detailed result and visualization of survival analysis. In summary, we believe that SurvivalMeth will facilitate prognostic research of DMFEs in diverse cancers.

[1]  Lianghong Zheng,et al.  DNA methylation markers for diagnosis and prognosis of common cancers , 2017, Proceedings of the National Academy of Sciences.

[2]  Wei Tang,et al.  Tumor origin detection with tissue‐specific miRNA and DNA methylation markers , 2018, Bioinform..

[3]  Dennis B. Troup,et al.  NCBI GEO: archive for functional genomics data sets—10 years on , 2010, Nucleic Acids Res..

[4]  Christopher M. Vockley,et al.  Genome-wide quantification of the effects of DNA methylation on human gene regulation , 2017, bioRxiv.

[5]  Yan Zhang,et al.  Lnc2Meth: a manually curated database of regulatory relationships between long non-coding RNAs and DNA methylation associated with human disease , 2017, Nucleic Acids Res..

[6]  K. Lillemoe,et al.  Aberrant Hypermethylation of Tumor Suppressor Genes in Pancreatic Endocrine Neoplasms , 2003, Annals of surgery.

[7]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[8]  D. Morton,et al.  CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma , 2009, Clinical Cancer Research.

[9]  O. Aalen.  A linear regression model for the analysis of life times. , 1989, Statistics in medicine.

[10]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[11]  Chirayu Pankaj Goswami,et al.  PROGgeneV2: enhancements on the existing database , 2014, BMC Cancer.

[12]  C. Lian,et al.  Epigenetic markers in melanoma. , 2015, Melanoma management.

[13]  Tieliu Shi,et al.  DNMIVD: DNA methylation interactive visualization database , 2019, Nucleic Acids Res..

[14]  K. Tomczak,et al.  The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge , 2015, Contemporary oncology.

[15]  M. Esteller,et al.  A prognostic DNA methylation signature for stage I non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Antunes,et al.  A DNA Methylation-Based Test for Breast Cancer Detection in Circulating Cell-Free DNA , 2018, Journal of clinical medicine.

[17]  Deruo Liu,et al.  Promoter methylation of APC and RAR-β genes as prognostic markers in non-small cell lung cancer (NSCLC). , 2016, Experimental and molecular pathology.

[18]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[19]  D. Stewart,et al.  Review Wnt Signaling Pathway in Non–small Cell Lung Cancer Overview of the Wnt Canonical (β-catenin) and Noncanonical Signaling Pathways , 2022 .

[20]  Torsten Hothorn,et al.  On the Exact Distribution of Maximally Selected Rank Statistics , 2002, Comput. Stat. Data Anal..

[21]  L. Benetatos,et al.  Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes , 2018, Cellular and Molecular Life Sciences.

[22]  A. Shilatifard,et al.  TET2 coactivates gene expression through demethylation of enhancers , 2018, Science Advances.

[23]  E. Borden,et al.  Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. , 2013, Matrix biology : journal of the International Society for Matrix Biology.

[24]  G. Hon,et al.  Adult tissue methylomes harbor epigenetic memory at embryonic enhancers , 2016 .

[25]  T. Masuda,et al.  Methylation status of the SOCS3 gene in human malignant melanomas. , 2007, International journal of oncology.

[26]  Andrzej K. Oleś,et al.  Drug-perturbation-based stratification of blood cancer , 2017, The Journal of clinical investigation.

[27]  H. Chu,et al.  DNA-methylation profiling distinguishes malignant melanomas from benign nevi , 2011, Pigment cell & melanoma research.

[28]  R. Shamir,et al.  Enhancer methylation dynamics contribute to cancer plasticity and patient mortality , 2016, Genome research.

[29]  Jian-Qun Chen,et al.  A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma , 2019, eLife.

[30]  M. Malumbres,et al.  Suppressor of cytokine signaling 1 blocks mitosis in human melanoma cells , 2012, Cellular and Molecular Life Sciences.

[31]  M. Yi,et al.  RASSF1A suppresses melanoma development by modulating apoptosis and cell‐cycle progression , 2011, Journal of cellular physiology.

[32]  Olof Akre,et al.  Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Matthew T. Maurano,et al.  Widespread plasticity in CTCF occupancy linked to DNA methylation , 2012, Genome research.

[34]  Sivan Sabato,et al.  DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes , 2013, Genome Biology.

[35]  Xiaojun Qian,et al.  APC gene promoter aberrant methylation in serum as a biomarker for breast cancer diagnosis: A meta‐analysis , 2018, Thoracic cancer.

[36]  C. Cordon-Cardo,et al.  Analysis of adenomatous polyposis coli gene expression, APC locus-microsatellite instability and APC promoter methylation in the progression of melanocytic tumours , 2004, Modern Pathology.

[37]  C. Dinarello,et al.  Dual role of apoptosis-associated speck-like protein containing a CARD (ASC) in tumorigenesis of human melanoma , 2012, The Journal of investigative dermatology.

[38]  Bin Zhang,et al.  DiseaseMeth version 2.0: a major expansion and update of the human disease methylation database , 2016, Nucleic Acids Res..

[39]  Gangning Liang,et al.  Gene body methylation can alter gene expression and is a therapeutic target in cancer. , 2014, Cancer cell.

[40]  A. Drilon,et al.  A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non–Small-Cell Lung Cancers , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[41]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[42]  Seung-Yong Jeong,et al.  Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer , 2016, British Journal of Cancer.

[43]  L. Cui,et al.  Association of APC, GSTP1 and SOCS1 promoter methylation with the risk of hepatocellular carcinoma: a meta-analysis , 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[44]  Matt Trau,et al.  DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer , 2015, Nature Communications.

[45]  J. Vilo,et al.  MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. , 2018, Epigenomics.

[46]  Mengtao Zhou,et al.  The DNA methylation profile of non-coding RNAs improves prognosis prediction for pancreatic adenocarcinoma , 2019, Cancer Cell International.

[47]  Chunlong Zhang,et al.  The Identification of Specific Methylation Patterns across Different Cancers , 2015, PloS one.

[48]  Clifford A. Meyer,et al.  Cistrome: an integrative platform for transcriptional regulation studies , 2011, Genome Biology.

[49]  D. Teti,et al.  DNA methylation-induced E-cadherin silencing is correlated with the clinicopathological features of melanoma. , 2016, Oncology reports.

[50]  S. Pedersen,et al.  The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers , 2018, Front. Oncol..

[51]  M. Valentine,et al.  Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN , 2002, Oncogene.

[52]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[53]  S. Goodman,et al.  Sensitive digital quantification of DNA methylation in clinical samples , 2009, Nature Biotechnology.

[54]  L. Hutchins,et al.  Methylation Profiling of Archived Non–Small Cell Lung Cancer: A Promising Prognostic System , 2005, Clinical Cancer Research.

[55]  Timothy J. Peters,et al.  Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling , 2016, Genome Biology.

[56]  L. Fisher,et al.  Time-dependent covariates in the Cox proportional-hazards regression model. , 1999, Annual review of public health.

[57]  J. Meyerhardt,et al.  Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. , 2014, Journal of the National Cancer Institute.

[58]  L. Bullinger,et al.  Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia. , 2017, Blood.

[59]  Q. Hou,et al.  Diagnostic Value of the Methylation of Multiple Gene Promoters in Serum in Hepatitis B Virus-Related Hepatocellular Carcinoma , 2017, Disease markers.

[60]  R. Kurzrock,et al.  Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. , 2018, Cancer treatment reviews.

[61]  V. Sollars,et al.  Silencing and re‐expression of retinoic acid receptor beta2 in human melanoma , 2010, Pigment cell & melanoma research.

[62]  Jian Zhang,et al.  SEdb: a comprehensive human super-enhancer database , 2018, Nucleic Acids Res..

[63]  M. Mekky,et al.  Studying the frequency of aberrant DNA methylation of APC, P14, and E-cadherin genes in HCV-related hepatocarcinogenesis. , 2018, Cancer biomarkers : section A of Disease markers.